Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma.
adverse events
immunotherapy
melanoma
programmed cell death-1 inhibitors
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
02
06
2022
received:
04
03
2022
accepted:
27
07
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
5
10
2022
Statut:
ppublish
Résumé
Melanoma is widely treated with programmed cell death-1 (PD-1) inhibitors. As part of their anti-tumor immunity effect, they increase the susceptibility to cutaneous immune-related adverse events (cIRAE) among other autoimmune effects. To characterize the manifestations of cIRAE in melanoma patients treated with PD-1 inhibitors, and evaluate the correlation with tumor response. A retrospective study of 95 metastatic malignant melanoma patients treated with PD-1 inhibitors at the Hadassah Medical Center during 2013-2016. The most common cIRAE was pruritus reported by 39 (41%) patients. All other cIRAE were noted in 34 patients (35.8%), of which the most common cutaneous manifestation was vitiligo, demonstrated in 17 patients (17.9%) followed by various rashes (7.4%, including erythema multiforme, oral lichen planus, photosensitive rash, insect bite-like reaction, and urticaria), psoriasiform rash (3.2%), bullous pemphigoid (3.2%), and eczema (1%). Interestingly, higher response rates to immunotherapy were demonstrated in patients who developed pruritus (85%) and cIRAE (88%), with lower mortality rates in the cIRAE group (38.2%) versus the non-cIRAE group (70.5%, p = 0.002). cIRAE are common among malignant melanoma patients treated with PD-1 inhibitors and may be a marker for favorable prognosis.
Identifiants
pubmed: 36190005
doi: 10.1111/dth.15747
pmc: PMC9786241
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15747Informations de copyright
© 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
Références
JAMA Dermatol. 2016 Jan;152(1):45-51
pubmed: 26501224
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
Melanoma Res. 2016 Oct;26(5):469-80
pubmed: 27306502
J Am Acad Dermatol. 2014 Jul;71(1):161-9
pubmed: 24767731
J Leukoc Biol. 2013 Jul;94(1):41-53
pubmed: 23667165
Cancers (Basel). 2019 Jul 26;11(8):
pubmed: 31357439
Dermatol Ther. 2022 Oct;35(10):e15747
pubmed: 36190005
J Clin Oncol. 2019 Oct 20;37(30):2746-2758
pubmed: 31216228
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Oncotarget. 2017 Jan 10;8(2):2171-2186
pubmed: 27974689
Eur J Cancer. 2016 Jun;60:12-25
pubmed: 27043866
JAMA Dermatol. 2015 Nov;151(11):1206-1212
pubmed: 26222619
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
J Am Acad Dermatol. 2020 Nov;83(5):1415-1424
pubmed: 32320766
Am J Clin Dermatol. 2018 Jun;19(3):345-361
pubmed: 29256113
J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
pubmed: 23291374
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268
pubmed: 32454097
J Am Acad Dermatol. 2019 Apr;80(4):990-997
pubmed: 30399387
J Am Acad Dermatol. 2013 Sep;69(3):e121-8
pubmed: 23357570
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Leuk Lymphoma. 2016 May;57(5):995-1001
pubmed: 26916355
J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1
pubmed: 26793994